Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19696498 | 0.78 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL353648 | 0.77 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL13866341 | 0.77 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18170201 | 0.76 | DRD2 (0.39) | SMYD2 | |
| SCHEMBL18170178 | 0.76 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL34476286 | 0.76 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL16833873 | 0.76 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL16840383 | 0.76 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL29203377 | 0.75 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22440238 | 0.74 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834526-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160311786-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311786-A1 | HIV PROTEASE INHIBITORS | PREP, PRSS1, CTSV | SMYD2 2345/4885CYP3A4 153/4885HTT 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.